HK1209973A1 - 蔥環類製劑 - Google Patents

蔥環類製劑

Info

Publication number
HK1209973A1
HK1209973A1 HK15111069.6A HK15111069A HK1209973A1 HK 1209973 A1 HK1209973 A1 HK 1209973A1 HK 15111069 A HK15111069 A HK 15111069A HK 1209973 A1 HK1209973 A1 HK 1209973A1
Authority
HK
Hong Kong
Prior art keywords
anthracycline
formulations
anthracycline formulations
Prior art date
Application number
HK15111069.6A
Other languages
English (en)
Inventor
Scott Geyer
Daniel Levitt
Carrie Nodgaard
Edward H Trappler
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Publication of HK1209973A1 publication Critical patent/HK1209973A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15111069.6A 2012-12-13 2015-11-10 蔥環類製劑 HK1209973A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737003P 2012-12-13 2012-12-13
PCT/US2013/075002 WO2014093815A1 (en) 2012-12-13 2013-12-13 Anthracycline formulations

Publications (1)

Publication Number Publication Date
HK1209973A1 true HK1209973A1 (zh) 2016-04-15

Family

ID=50934989

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111069.6A HK1209973A1 (zh) 2012-12-13 2015-11-10 蔥環類製劑

Country Status (8)

Country Link
US (2) US20150342975A1 (zh)
EP (2) EP3915369A1 (zh)
JP (5) JP6433913B2 (zh)
AU (1) AU2013359048A1 (zh)
CA (1) CA2894548C (zh)
DK (1) DK2931042T3 (zh)
HK (1) HK1209973A1 (zh)
WO (1) WO2014093815A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894548C (en) * 2012-12-13 2021-01-12 Cytrx Corporation Anthracycline formulations
NZ631022A (en) 2013-06-05 2018-05-25 Cytrx Corp Cytotoxic agents for the treatment of cancer
MX2018002293A (es) 2015-08-25 2018-09-05 Nantomics Llc Sistemas y métodos para las llamadas variantes de alta precisión.
US11071812B2 (en) * 2016-05-31 2021-07-27 Penumbra, Inc. Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood
WO2019036485A1 (en) 2017-08-15 2019-02-21 Nantcell, Inc. ASSOCIATIONS OF CÉTUXIMAB AND HIGH AFFINITY NATURAL KILLER CELLS AND ASSOCIATED METHODS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
JP2915252B2 (ja) 1993-06-30 1999-07-05 明治製菓株式会社 溶解性が改善された製剤の製造法
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
JP5634862B2 (ja) * 2007-05-16 2014-12-03 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低粘度アントラサイクリン製剤
EP2216049A1 (en) * 2009-02-06 2010-08-11 Freie Universität Berlin Drug conjugates with polyglycerols
RU2531591C2 (ru) * 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
CA2894548C (en) * 2012-12-13 2021-01-12 Cytrx Corporation Anthracycline formulations

Also Published As

Publication number Publication date
AU2013359048A1 (en) 2015-07-02
JP2016503026A (ja) 2016-02-01
EP2931042A1 (en) 2015-10-21
US10328093B2 (en) 2019-06-25
JP2021120414A (ja) 2021-08-19
EP3915369A1 (en) 2021-12-01
JP6833768B2 (ja) 2021-02-24
JP7213303B2 (ja) 2023-01-26
JP2019206583A (ja) 2019-12-05
JP6433913B2 (ja) 2018-12-05
CA2894548A1 (en) 2014-06-19
JP2018165280A (ja) 2018-10-25
WO2014093815A1 (en) 2014-06-19
CA2894548C (en) 2021-01-12
US20170340655A1 (en) 2017-11-30
JP2021120415A (ja) 2021-08-19
US20150342975A1 (en) 2015-12-03
DK2931042T3 (da) 2021-06-07
EP2931042A4 (en) 2016-06-01
EP2931042B1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
HK1255929A1 (zh) 前體脂質體睾酮製劑
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
HUE058912T2 (hu) Liposzóma készítmények
EP2861218A4 (en) LIPOSOME FORMULATIONS
HK1209973A1 (zh) 蔥環類製劑
PL2908835T3 (pl) Stabilne formulacje
RS56980B1 (sr) Biljne formulacije
GB201110278D0 (en) Formulations
GB201221125D0 (en) Pharmaceutial formulations
GB201206178D0 (en) Formulations
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201104049D0 (en) Formulations
GB201102795D0 (en) Formulations